Almanac A1C

Beyond the Injection: Natural Strategies to Harness Your Body’s GLP-1 Response for Metabolic Health

Posted

by

A1C Medical Writer 2

Table of Contents
Keywords: , , , , , ,

Introduction

Glucagon-Like Peptide-1 (GLP-1) helps regulate metabolic health by increasing insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, resulting in better blood sugar control and weight management. Natural strategies- such as high-fiber and protein-rich diets, healthy fats, and regular physical activity- can help support and enhance the body’s GLP-1 response, offering drug- free tools for improving metabolic outcomes.

Physiological Roles of GLP-1

Glucagon-Like Peptide-1 (GLP-1)is an incretin hormone with critical physiological roles in metabolic regulation, gut-brain signalling, and cardiovascular health. Below is a detailed, evidence- based overview of GLP-1’s main functions, relevant for clinical research and supplement science.

Metabolic Regulation

GLP-1 is secreted from intestinal L-cells in response to food intake and plays a direct role in modulating glucose homeostasis. Its major actions include:

  • Stimulating glucose-dependent insulin secretion from pancreatic beta cells, thereby lowering postprandial blood glucose levels.
  • Suppressing glucagon secretion from alpha cells, reducing hepatic glucose output.
  • Slowing gastric emptying, which dampens the rate at which glucose enters the bloodstream.

These effects make GLP-1 a key target for antidiabetic drugs, notably GLP-1 receptor agonists [1].

Appetite and Weight Regulation

GLP-1 impacts the central nervous system:

  • Promoting satiety and reducing food intake via hypothalamic pathways, contributing to weight loss.
  • Modulating reward and hedonic eating behaviours, which relates to its use in obesity management.

Cardiovascular Effects

GLP-1 has notable cardiovascular actions:

  • Improving endothelial function and promoting vasodilation, which optimizes blood flow.
  • Reducing blood pressure and potentially protecting myocardium against ischemic injury.
  • Clinical trials with GLP-1 agonist show beneficial effects on cardiovascular outcomes in patients with type 2 diabetes.

Neuroprotective Actions

GLP-1 is also recognized for neuroprotection:

  • Enhancing neuronal survival and reducing neuroinflammation in preclinical models.
  • Improving cognitive function and memory through central receptor activation, sparking interest for potential roles in Alzheimer’s disease.

Additional Effects

Other reported physiological roles include [2,3]:

  • Supporting beta-cell proliferation and survival, vital for pancreatic health.
  • Influencing gastric motility and secretion, relevant for disorders like gastroparesis.
  • Interacting with immune pathways and exhibiting anti-inflammatory effects in metabolic issues.

GLP-1 in Obesity

GLP-1 (Glucagon-Like Peptide-1) plays multi-dimensional roles in obesity through appetite regulation, metabolic effects, and direct pharmacological intervention [4-9].

Central and Peripheral Appetite Regulation

GLP-1 is secreted by intestinal L-cells after food intake and acts as a satiety signal:

  • In both animals and humans, GLP-1 reduces hunger, food intake, and promotes satiety by activating receptors in key areas of the hypothalamus, brainstem, mesolimbic system [4,5,6].
  • This action involves slowing gastric emptying, enhancing fullness, and directly acting on the central nervous system to reduce meal size and snacking behaviour [6,7].

Weight Loss and Metabolic Effects

  • GLP-1 receptor agonists (GLP-1 Ras) are effective anti-obesity treatments. A meta-analysis of 47 RCTs (23,244 patients) showed GLP-1 Ras led to an average weight loss of -4.6kg, BMI reduction of -2.1kg/m^2, waist circumference reduction of -4.6 cm compared to placebo [4,5].
  • The magnitude of weight loss is greatest with longer duration, higher baseline obesity, and in patients with no diabetes [5].
  • GLP-1 also decreases postprandial insulin and glucagon responses, which improves metabolic control alongside body weight reduction[8].

Mechanisms in Obesity Pathophysiology

  • Obese individuals may have impaired GLP-1 action or reduced postprandial GLP-1 secretion, contributing to dysregulated satiety and increased gastric emptying rates [8].
  • GLP-1 acts via neural pathways (vagal afferents) to delay gastric emptying, enhance fullness, and signal satiety to the brain, forming a gut-brain axis relevant for obesity therapeutics [7,9].
  • Impairment of these mechanisms may bridge the link between obesity and the development of type 2 diabetes [8].

Pharmacologic Implications and Clinical Outcomes

  • GLP-1 Ras support sustained weight loss, and their use leads to improved glycemic control and favourable cardiovascular risk reduction in obese patients-independent of diabetes status [5,6,10].
  • After discontinuation, weight regain may occur if not combined with lifestyle actions like exercise, underscoring the need for multimodal approaches [5,11].

Concerns With GLP-1 Medications

GLP-1 medications- while highly effective for diabetes and obesity- present important concerns that should be addressed in clinical practice, research, and patient education [12,13,14,15,16].

Common and Gastrointestinal Side Effects

  • The most frequent adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, bloating, and stomach pain. They are typically most prominent at the start of therapy or following dose increases, affecting up to 50% of patients, but often improve with time [13,14,15,16].
  • Some individuals may experience indigestion, heartburn, dizziness, and fatigue [13,14,16].

Serious, Less Common Risks

  • **Pancreatitis and gallbladder disease (**cholecystitis, cholelithiasis, biliary obstruction) are rare but potentially severe complications. The risk increases with higher dose and longer durations [13,14,17].
  • Acute kidney injury and dehydration may occur, typically secondary to severe gastrointestinal symptoms and fluid loss [12,15].
  • A boxed warning exists for the potential risk of thyroid C-cell tumors, but human evidence is inconclusive, and surveillance is ongoing [13,15].
  • Increased heart rate and mild tachycardia, as well as injection site reactions and allergy risk (including possible anaphylaxis), have been reported [7,18].

Long- term, Metabolic, and Safety Concerns

  • Weight Regain Post-discontinuation: Most individuals regain part or all of the lost weight after stopping GLP-1 therapy, which raises concerns about lifelong medication reliance, cost, and accessibility [19].
  • Lean Muscle Loss and Nutrient Deficiencies: Significant declines in muscle mass and reduced nutrient absorption may occur due to prolonged appetite suppression, leading to risk for B12, iron, and calcium deficiencies [19].
  • Potential for Endocrine Disruption: Extended use could affect natural metabolic rhythms, and long-term effects on gastrointestinal and hormonal function require further study [19].
  • Retinopathy Risk: Rapid glucose lowering may exacerbate diabetic retinopathy in susceptible patients, warranting dedicated monitoring [13].

Practical Considerations

  • GLP -1 medications are generally well tolerated, but side effects are a common reason for treatment discontinuation [15,20].
  • Not recommended during pregnancy due to risks of developmental abnormalities [15,18].
  • Monitoring for misuse, especially in populations not meeting prescribing criteria for weight loss, is important [7,21].

A Practical, Evidence-Based Approach to GLP-1 Agonist Use

A practical, evidence-based approach to GLP-1 agonist use involves clear patient selection, individualized initiation and titration, proactive monitoring, and integration of lifestyle strategies- all underpinned by recent clinical guidelines and real-world evidence [18,22,23,24,25].

Patient Selection and Indications

  • Type 2 Diabetes and Obesity: GLP-1 receptor agonists are recommended for patients with type 2 diabetes who are overweight/obese or have established cardiovascular disease, heart failure, or chronic kidney disease. They are also approved for chronic weight management in patients with a BMI ≥27 kg/m^2 with comorbidities or BMI ≥30 kg/m^2 alone [18,23].
  • Contraindications: Avoid use in patients with a history of medullary thyroid carcinoma, pancreatitis, or type 1 diabetes; not recommended in pregnancy or breastfeeding [18,24].

Initiation and Dose Titration

  • Start Low, Go Slow: Initiate with the lowest available dose and titrate upwards every 1-4 weeks to minimize gastrointestinal side effects (nausea, vomiting) [18,25].
  • Drug Formulation Choice: Once-weekly formulations (e.g., semaglutide, dulaglutide) generally improve patient adherence and persistence compared to daily injections [26].
  • Education: Counsel patients on what to expect regarding side effects, satiety changes, and when to adjust dosing [18,25].

Monitoring and Safety

  • Gastrointestinal Symptoms: Track for nausea, vomiting, diarrhea, and constipation-most improve over time but require prompt reporting [22,25].
  • Weight, Glycemic Control, Cardiovascular Parameters: Regularly monitor weight, HbA1c, blood pressure, and kidney function [24,25].
  • Remote Monitoring: Incorporate remote patient monitoring platforms to increase engagement, adherence, and early detection of side effects.
  • Adverse Effects: Watch for rare complications (pancreatitis, gallbladder issues, possible thyroid concerns) [25,26].

Ongoing Adjustments and Lifestyle Integration

  • Dose Adjustment: Modify dose as needed based on side effects and treatment goals. Consider switching to more convenient formulations if adherence is an issue [25,26].
  • Diet and Activity: Encourage high-fiber foods, adequate hydration, and physical activity for natural support of GLP-1 action [25].
  • Discontinuation/ Transition: Prepare for weight regain risk after discontinuation- emphasize ongoing lifestyle support [19,22].

Dual GLP-1 and GIP Receptor Agonist

A dual GLP-1 and GIP receptor agonist is a pharmacological agent designed to simultaneously activate both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, offering synergistic effects on metabolic regulation, especially for type 2 diabetes and obesity management [28,29,30].

Mechanism of Action

Dual agonist bind to both GLP-1 and GIP receptors, stimulating insulin secretion from pancreatic b-cells in glucose-dependent manner while suppressing inappropriate glucagon secretion. GLP-1 activation curbs appetite, enhances satiety, and promotes lipolysis, whereas GIP supports insulin secretion, enhances b- cell function, and drives lipogenesis but also has contextual effects on glucagon, especially during hypoglycemia. Together, dual agonists harmonize metabolic responses- GLP-1 acts as glucagonostatic at high glucose while GIP can exert glucagonotropic effects under low glucose conditions; this tandem action supports tighter glycemic control and improved lipid profile [29,30].

Metabolic Benefits and Clinical Evidence

Dual agonists, such as tirzepatide (LY3298176), outperform single receptor agonists in clinical studies by providing better glucose lowering and greater weight reduction over periods ranging from 12 to 26 weeks in patients with type 2 diabetes. For example, tirzepatide resulted in A1c reductions from -1.06% to -1.94% across doses, outperforming GLP-1 single agonists like dulaglutide, and consistently showed added anti-obesity properties. These drugs also contribute to reduced cardiovascular risk and improved adipokine profiles [28,29,30].

Molecular and Physiological Synergy

At the cellular level, simultaneous activation of both receptors augments cAMP signaling in b- cells, further boosting insulinotropic responses beyond what either hormone achieves alone. GLP-1’s signature effect remains appetite suppression, while the presence of GIP can sensitize GLP-1 signaling in metabolic tissues and overcome deficits in GIP responsiveness that often arise in poorly controlled diabetes [29,30,31].

Relevance for Drug Development

Unimolecular dual agonists represent a major advance, combining two incretin effects within one peptide to maximize efficacy in glycemic and weight control. This approach is driving the next generation of metabolic therapies- including ongoing research into tri-agonists, which add glucagon receptor activity to further broaden the spectrum of metabolic benefits [28,32].

Natural Strategies to Boost GLP-1

Several natural strategies can help boost GLP-1 secretion and its beneficial metabolic effects, including dietary choice, lifestyle habits, and stress management. Below are detailed mechanisms and supporting references for each strategy [33,34,35,36].

Yerba Mate

Yerba mate (Ilex paraguariensis) has been shown in animal and small human studies to increase GLP-1 levels, promote satiety, and reduce body fat. The active compounds, such as caffoyl quinic acids and matesaponins, directly stimulate GLP-1 secretion and increase leptin-leading to appetite suppression [35,37].

Allulose

Allulose, a rare sugar and fructose epimer, stimulates GLP-1 secretion through a unique mechanism of intestinal distension after oral intake.  The greater the intestinal content volume following allulose administration, the stronger the GLP-1 release. This effect occurs without significantly affecting other satiety hormones like GIP or PYY [38,39].

Low Carbohydrate and Optimized Diet

Low carbohydrate diets minimize postprandial glucose spikes and allow improved insulin sensitivity, Balanced diets with whole grains, fruits, vegetables, and lean proteins stimulate GLP-1 naturally via nutrient sensing in the intestines. Monounsaturated fats (olive oil, avocado) and nuts (e.g., pistachios, high in fiber and healthy fats) further raise GLP-1 response [34,40,41].

Collagen Peptides and High Protein Foods

Dietary protein and collagen peptides stimulate GLP-1 secretion through the chemosensory activation in the gut. Specific amino acids (L-glutamine, L-phenylalanine, L-alanine) potently enhance GLP-1 secretion during digestion, especially when coupled with calcium. High protein intake can help maintain satiety and support glycemic control [34,40,41].

Fiber Intake

Increased fiber intake promotes GLP-1 secretion through fermentation in the gut, producing short-chain fatty acids (SCFAs). These SCFAs directly activate intestinal L-cells, raising GLP-1. Barley (beta-glucan) and digestion-resistant fibers like Fibersol® have demonstrated significant increases in satiety hormones after consumption [42,43].

Regular Physical Activity

Exercise increases GLP-1 levels in both healthy and overweight individuals. Acute and chronic moderate-to high-intensity training improves GLP-1 secretion and/or resistance, partly by enhancing gut microbiota diversity and promoting metabolic flexibility [44].

Prioritizing Sleep

Adequate sleep helps synchronize GLP-1 secretion and postprandial satiety response. Sleep deprivation delays GLP-1 peaks after meals, impairing metabolic regulation. Prioritizing good sleep hygiene maintains optimal GLP-1 response and appetite regulation [45].

Stress Management

Chronic stress and its associated hormonal changes influence central GLP-1 signalling. Managing stress-through mindfulness, relaxation, and positive social engagement-can support a healthier GLP-1 profile by reducing over-activation of the hypothalamic pituitary adrenal axis, helping maintain appetite regulation and optimal metabolic response [46,47].

Conclusion

GLP-1 plays a pivotal role in metabolic health, acting through insulin secretion, glucagon suppression, appetite control, cardiovascular protection, and neuroprotection. Pharmacologic GLP-1 agonists are effective in promoting weight loss, glycemic control and cardiovascular risk reduction, but their use requires careful consideration due to potential side effects and safety concerns. Importantly, natural strategies-such as dietary optimization (high fiber, protein, healthy fats), regular exercise, quality sleep, stress management, and functional foods (yerba mate, allulose)- offer safe, sustainable pathways to augment GLP-1 activity and support long-term health without the risk or costs associated with lifelong medication.

Recommendations

For individuals seeking weight loss, prioritizing natural methods is paramount. Intermittent fasting, regular exercise encompassing both cardiovascular and resistance training, and balanced dietary approaches rich in protein, fiber, and healthy fats should be the first line of defense. These strategies not only facilitate weight loss but also offer a cascade of additional health benefits, including improved insulin sensitivity, enhanced mental clarity, reduced inflammation, and sustained metabolic rate. Complementing these lifestyle changes with natural GLP-1 boosting strategies like yerba mate consumption, incorporating allulose into the diet, prioritizing protein intake, increasing fiber consumption, and ensuring adequate sleep can further enhance satiety and optimize metabolic health.

While GLP-1 receptor agonists may present a tempting shortcut, their use should be reserved for carefully selected individuals under strict medical supervision. These are individuals who have genuinely exhausted all natural methods without achieving significant and sustainable weight loss, or those with specific health conditions such as type 2 diabetes or metabolic syndrome, where the benefits of GLP-1 agonism may outweigh the risks. Even when pharmacological intervention is deemed necessary, continuing to prioritize natural GLP-1 boosting strategies alongside prescribed GLP-1 agonists can potentially reduce the required dosage, minimize side effects, and contribute to a more sustainable long-term outcome. Importantly, individuals should consult with their healthcare provider to explore all treatment options and to weigh the potential risks and benefits of GLP-1 agonists against other available pharmacological interventions and lifestyle modifications, receiving individualized treatment approach.

References

  1. Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. “The New Biology and Pharmacology of Glucagon-Like Peptide-1.” Horm Metab Res. 2020;52(9):537-548.
  2. Drucker DJ. “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.” Diabetologia. 2022;65(12):1905-1916.
  3. Zelniker TA, Wiviott SD, Raz I, Sabatine MS. “GLP-1 Receptor Agonists for Cardiovascular Risk reduction in Type 2 Diabetes.” Nat Rev Cardiol. 2021:18(1):18-34.
  4. Wang JY, et al. “GLP-1receptor agonists for the treatment of obesity.” Front Endocrinol (Lausanne). 2023; PMC9945324.
  5. Madsbad S. “The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.” Diabetes Obes Metab. 2014;16(1);9-21. PMID:23617798.
  6. Drucker DJ. “GLP-1 physiology informs the pharmacotherapy of obesity.” Trends Mol Med. 2022;28(2);98-114.
  7. Cleveland Clinic. GLP-1 agonists [Internet]. Cleveland Clinic. 2023. Available from: https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
  8. Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nature reviews Drug discovery [Internet]. 2025;10.1038/s41573-02501183-8. Available from: https://pubmed.ncbi.nlm.nih.gov/40281304/
  9. Cai CY, et al. “Mechanisms of action and therapeutic applications of GLP-1 and GIP.” Front Endocrinol (Lausanne). 2024;1431292.
  10. Shah M, Vella A. “Effects of GLP-1 on appetite and weight.” Rev Endocr Metab Disord. 2013; PMC4119845.
  11. Wong HJ, et al. “Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference.” Diabetes Care. 2025;48(2);292-303.
  12. Sauerwein K. Study identifies benefits, risks linked to popular weight-loss drugs | WashU Medicine [Internet]. WashU Medicine. 2025. Available from: https://medicine.washu.edu/news/study-identifies-benefits-risks-linked-to-popular-weight-loss-drugs/
  13. Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes care [Internet]. 2024 Jun 6;47(11). Available from: https://diabetesjournals.org/care/article/47/11/1873/156807/Efficacy-and-Safety-of-GLP-1-Medicines-for-Type-2
  14. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. The Review of Diabetic Studies [Internet]. 2015 Feb 10;11(3-4):202–30. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397288/
  15. Billingsley A. 10 GLP-1 Side Effects You Should Know About [Internet]. GoodRx. 2025. Available from: https://www.goodrx.com/classes/glp-1-agonists/glp-1-side-effects
  16. Catanese L. GLP-1 diabetes and weight-loss drug side effects: [Internet]. Harvard Health. 2024. Available from: https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more
  17. Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse [Internet]. GOV.UK. 2024. Available from: https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse
  18. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/
  19. Jankovic B. Assessing the Benefits, Risks, and Long-Term Metabolic Effects of GLP-1 Agonists – Dr. Bojana [Internet]. Dr. Bojana. 2025 [cited 2025 Aug 28]. Available from: https://drbojana.com/assessing-the-benefits-risks-and-long-term-metabolic-effects-of-glp-1-agonists/
  20. Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obesity Pillars. 2024 Dec;12:100127.
  21. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss [Internet]. U.S. Food and Drug Administration. 2024. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  22. GLP1RA therapy in type 2 diabetes [Internet]. Australian Journal of General Practice. 2022. Available from: https://www1.racgp.org.au/ajgp/2022/july/glp1ra-therapy-in-type-2-diabetes
  23. Ruxandra Christodorescu. Part II. Highlights from the clinical consensus statement by the European Society of Cardiology on obesity and cardiovascular disease: pharmacological and bariatric treatment strategies [Internet]. Escardio.org. 2024. Available from: https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopractice/part-II-highlights-from-the-clinical-consensus-statement-by-the-european-society
  24. Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, et al. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgery for Obesity and Related Diseases [Internet]. 2024 Oct 29;20(12). Available from: https://www.sciencedirect.com/science/article/pii/S1550728924007949
  25. Saleh Fahad Alqifari, Alkomi O, Esmail A, Khadijeh Alkhawami, Shahd Yousri, Mohamad Ayham Muqresh, et al. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus. World journal of diabetes. 2024 Mar 15;15(3):331–47.
  26. Almandoz JP, Lingvay I, Morales J, Campos C. Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clinical Diabetes [Internet]. 2020 May 15;38(4):390–402. Available from: https://clinical.diabetesjournals.org/content/diaclin/early/2020/05/13/cd19-0100.full.pdf
  27. 5 Key Benefits of Remote Patient Monitoring (RPM) in GLP-1 treatment for Weight Loss | vitalera Blog [Internet]. Vitalera.io. 2024 [cited 2025 Aug 28]. Available from: https://www.vitalera.io/blog-posts/5-key-benefits-of-remote-patient-monitoring-rpm-in-glp-1-treatment-for-weight-loss
  28. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018 Dec;18:3–14.
  29. Qiyuan Keith Liu. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology [Internet]. 2024 Jul 24;15. Available from: https://pubmed.ncbi.nlm.nih.gov/39114288/
  30. Rizvi AA, Rizzo M. The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy [Internet]. 2022 Apr 5;15:1023–30. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994606/
  31. Wang L. Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP. Drug Design, Development and Therapy. 2022 May;Volume 16:1547–59.
  32. Zafer M, Tavaglione F, Romero‐Gómez M, Rohit Loomba. Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Alimentary Pharmacology & Therapeutics. 2025 May 13;
  33. Kolhe RC, Chaudhari PS, Khaire MP, Ghadage PK, More AS. Natural Bioactives Targeting the GLP-1 Pathway: A Promising Approach for Diabetes Management. Pharmacognosy Reviews [Internet]. 2025 May 28 [cited 2025 Aug 28];19(37):1–14. Available from: https://phcogrev.com/sites/default/files/PharmacognRev-19-37-1.pdf
  34. Pedersen T. What Foods Increase GLP-1 Levels? [Internet]. Healthline. Healthline Media; 2024. Available from: https://www.healthline.com/health/foods-that-increase-glp-1
  35. Rowe N. How to Increase GLP-1 Naturally With Supplements and Foods [Internet]. GoodRx. 2024. Available from: https://www.goodrx.com/conditions/weight-loss/how-to-increase-glp-1-naturally
  36. Pumper C. How to activate GLP-1 naturally [Internet]. Osu.edu. The Ohio State University; 2025. Available from: https://health.osu.edu/wellness/exercise-and-nutrition/activiating-glp-1-naturally
  37. Hussein GME, Matsuda H, Nakamura S, Hamao M, Akiyama T, Tamura K, et al. Mate tea (Ilex paraguariensis) promotes satiety and body weight lowering in mice: involvement of glucagon-like peptide-1. Biological & Pharmaceutical Bulletin [Internet]. 2011 [cited 2023 Apr 10];34(12):1849–55. Available from: https://pubmed.ncbi.nlm.nih.gov/22130241/
  38. Iwasaki Y, Michizo Sendo, Katsuya Dezaki, Hira T, Sato T, Nakata M, et al. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nature Communications. 2018 Jan 9;9(1).
  39. Mizuma S, Hayakawa M, Hira T. Intestinal Distension Induced by Luminal D-allulose Promotes GLP-1 Secretion in Male Rats. Endocrinology [Internet]. 2025 Jun;166(2):bqaf002. Available from: https://pubmed.ncbi.nlm.nih.gov/39821080/
  40. Scourboutakos M. What and how you eat can increase the effects of GLP-1 without drugs. 2025 May 15 [cited 2025 Aug 28]; Available from: https://theconversation.com/what-and-how-you-eat-can-increase-the-effects-of-glp-1-without-drugs-253728
  41. Migala J. Can You Boost GLP-1 Naturally? [Internet]. WebMD. 2024. Available from: https://www.webmd.com/obesity/features/natural-glp1-boosters
  42. Michaeleen Doucleff. Less snacking, more satisfaction: Some foods boost levels of an Ozempic-like hormone [Internet]. NPR. NPR; 2023. Available from: https://www.npr.org/sections/health-shots/2023/10/30/1208883691/diet-ozempic-wegovy-weight-loss-fiber-glp-1-diabetes-barley
  43. Fiber’s Fit for GLP-1 Consumers [Internet]. Fibersol. 2022 [cited 2025 Aug 28]. Available from: https://fibersol.com/blog/fibers-fit-for-glp-1-consumers
  44. Hamasaki H. Exercise and glucagon-like peptide-1: Does exercise potentiate the effect of treatment? World Journal of Diabetes. 2018 Aug 15;9(8):138–40.
  45. Benedict C, Barclay JL, Ott V, Oster H, Hallschmid M. Acute sleep deprivation delays the glucagon-like peptide 1 peak response to breakfast in healthy men. Nutrition & Diabetes [Internet]. 2013 Jun 1 [cited 2022 Jan 24];3(6):e78–8. Available from: https://www.nature.com/articles/nutd201320
  46. Ghosal S, Myers B, Herman JP. Role of central glucagon-like peptide-1 in stress regulation. Physiology & Behavior. 2013 Oct;122:201–7.
  47. Holt MK, Trapp S. The physiological role of the brain GLP-1 system in stress. Cogent biology. 2016 Sep 14;2(1):1229086–6.